What Alkem Laboratories does

Alkem Laboratories is an India-headquartered, publicly listed pharmaceutical company (NSE: ALKEM) founded in 1973 that develops, manufactures, and markets generic formulations, specialty pharmaceuticals, biosimilars, and active pharmaceutical ingredients (APIs) across more than 13 therapeutic areas, including anti-infectives, gastroenterology, cardiology, neurology, diabetology, oncology, and ophthalmology. The portfolio spans over 800 brands and 1,300+ SKUs, anchored by category-leading franchises such as PAN (#1 in PPI market), PAN-D (#1 in PPI+Domperidone), Clavam (Rs 6 billion+ in domestic sales), and Taxim-O, alongside a biosimilars pipeline (Rituximab, Bevacizumab, Trastuzumab, Teriparatide, Adalimumab) developed through subsidiary Enzene Biosciences. The company operates 18 manufacturing facilities meeting USFDA and EU GMP standards and runs three global R&D centres staffed by 500+ scientists focused on formulation development, BA/BE studies, and complex generics such as pre-filled syringes, injection pens, and orodispersible tablets.

Name

Alkem Laboratories

Legal name

Alkem Laboratories Ltd.

Website

https://alkemlabs.com

Company type

Public

Founded year

1973

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Alkem Laboratories is an India-based, publicly listed pharmaceutical company that manufactures and markets generic formulations, biosimilars, and APIs across 13+ therapeutic areas in over 40 countries, serving patients through retail pharmacies, hospitals, and institutional buyers via subsidiaries like Ascend and Enzene.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Generic pharmaceutical formulations
• Biosimilar manufacturing
• Active pharmaceutical ingredients
• Pharmaceutical contract development
• Branded generic medicines

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices19 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. India Formulations (Domestic): Domestic pharmaceutical formulations business in India, generating over 70% of revenue. Includes branded generics across multiple therapy areas through direct sales force targeting doctors, hospitals, and pharmacies.
2. US Generics Business: Sales of generic pharmaceutical products in the United States through Ascend Laboratories subsidiary. Cumulatively filed over 144 ANDAs with US FDA. Revenue from US market crossed US$200 million annually.
3. International Markets: Operations across LATAM, Europe, Africa, CIS, Southeast Asia, and Australia through subsidiaries and distribution partnerships. Products marketed in about 50 international markets directly and indirectly.
4. GLP-1 Franchise (Semaglutide): New product line following semaglutide patent expiry in India, including injection pens and pre-filled syringes for diabetes and weight management. Achieved approximately 11% unit market share in India.

Pricing tiers

Go-to-market motion3 records

Distribution channels8 records

Marketing channels10 records

Core offering

Alkem Laboratories develops, manufactures, and sells generic pharmaceutical formulations, biosimilars (monoclonal antibodies), and Active Pharmaceutical Ingredients (APIs) across 13 therapy areas including anti-infective, gastroenterology, cardiology, diabetology, oncology, neurology, respiratory, ophthalmology, dermatology, rheumatology, urology, gynaecology, and anti-osteoporosis. The company markets 800+ brands and 1,300+ SKUs through subsidiaries such as Ascend Laboratories (US), Enzene Biosciences (biosimilars), and Pharmacor (Australia) across 40+ countries.

Product overview

Alkem Laboratories is a pharmaceutical company offering a broad portfolio of generic and specialty pharmaceutical formulations across multiple therapeutic areas. The company operates through multiple subsidiaries including Ascend Laboratories (US), Enzene Biosciences (biosimilars), and Pharmacor (Australia). Core products include well-established brands like Clavam, Pan, Pan-D, and Taxim-O in anti-infectives and gastroenterology. The company has expanded into diabetes/obesity care with semaglutide products (Semasize, Obesema, Hepaglide) launched in 2026, and offers biosimilar monoclonal antibodies (Rituximab, Bevacizumab, Trastuzumab) for oncology. The portfolio spans 13 therapeutic areas including Anti-infective, Cardiology, Neurology, Dermatology, Diabetology, Gastroenterology, Gynaecology, Oncology, Ophthalmology, Respiratory, Rheumatology, and Urology, with over 800 brands and 1,300+ SKUs. International operations cover US, Australia, Europe, Latin America, and emerging markets.

Differentiator

Problem solved

Functional benefit

Brands

• Clavam: Anti-infective brand; one of Alkem's pillar brands in anti-infective therapy area.
• Pan
• Pan-D
• Taxim-O
• Ondem
• Emty
• Glucoryl
• Dapanorm
• Cytomab
• Advamab
• Hersima
• GEMCAL
• GEMTIDE
• Clindac-A
• RENOCIA
• MABVINRA
• TOFE

Products and services

• Clavam Anti-infective brand of amoxicillin and clavulanic acid combination available in dry syrups, tablets, and injections for treatment of bacterial infections.
• Pan Pantoprazole-based gastroenterology product ranked #1 in the PPI market by sales value, with variants including PAN 80 for refractory GERD treatment.
• Pan-D Pantoprazole and domperidone combination ranked #1 in the PPI+Domperidone market by sales value.
• Taxim-O Anti-infective brand based on cefixime; leader in its segment and India's first anti-infective drug to surpass Rs. 1,000 million in domestic sales.
• Cytomab (Rituximab biosimilar) Monoclonal antibody biosimilar for treatment of Non-Hodgkin's Lymphoma and autoimmune disorders including rheumatoid arthritis.
• Advamab (Bevacizumab biosimilar) Monoclonal antibody biosimilar for treatment of advanced colorectal cancer and recurrent ovarian cancer.
• Hersima (Trastuzumab biosimilar) Monoclonal antibody biosimilar for HER2+ breast cancer and HER2+ gastric cancer.
• Semaglutide (Semasize, Obesema, Hepaglide) Generic semaglutide products launched in India for diabetes and weight management following patent expiry; available in injection pens (Rs 1,800/month) and pre-filled syringes (from Rs 350).
• Semaglutide Pre-filled Syringes India's first ready-to-use single-shot Semaglutide pre-filled syringes approved by DCGI for Type 2 diabetes and obesity management in multiple dose strengths starting at Rs 350.
• A to Z Daily Multivitamin Multivitamin supplement for adults formulated with 26 vitamins, minerals, and botanicals supporting physical and mental health, energy, immunity, and stress management.
• GEMTIDE (Teriparatide biosimilar) Anabolic biosimilar injection for building new bones in patients with severe osteoporosis and high risk of fractures.
• GEMCAL Range Calcium supplementation product range including GEMCAL, GEMCAL D3, and GEMCAL DS for osteoporosis management and calcium deficiency.
• Olkem (Olmesartan) Cardiology brand for hypertension management based on Olmesartan.
• Jupiros (Rosuvastatin) Cardiology brand for dyslipidemia management based on Rosuvastatin.
• TICAVIC (Ticagrelor) Anti-platelet cardiology brand based on Ticagrelor for cardiovascular conditions.
• DONEP Neurology brand of Donepezil for treatment of Alzheimer's disease, available in multiple strengths and formulations.
• PENTANERVE NT Neurology brand combining Gabapentin and Nortriptyline for neuropathic pain management.
• Alkem Wellness Wellness product portfolio including nutraceuticals and supplements marketed directly to consumers through alkemwellness.com.

Quantifiable outcome

• Semaglutide achieved approximately 11% unit market share in India within months of March 2026 launch
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Occlutech Holding AGcoreStrategic or Co-development Partner · 26 June 2026Alkem Medtech Private Limited (wholly owned subsidiary) executing First Supplementary Agreement to acquire 51%-55% stake in Switzerland-based Occlutech Holding AG for approximately $118 million (EUR 99.4 million). Transaction modifies original SPA from March 6, 2026. Occlutech is second-largest player in Europe and third-largest globally in minimally invasive cardiac implants with revenues of €49.4 million in 2025.
• DMIC Vikram Udyogpuri LtdminorOthers · 18 March 2026Land allotment for 30 acres at Ujjain, Madhya Pradesh for greenfield formulations manufacturing facility. Investment increased from Rs 533 crore to Rs 1,036 crore.
• Esperion Therapeutics Inc.minorOthers · 17 February 2026Settlement agreement resolving patent litigation concerning generic versions of cholesterol drugs NEXLETOL and NEXLIZET. Alkem agreed not to launch generic versions in US before April 19, 2040. Settlement covers only Alkem; litigation continues against other defendants.
• Haw ParminorStrategic or Co-development PartnerMarketing alliance to exclusively market, sell and distribute Tiger Balm range of products in India.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Sun Pharmaceutical Industries: India's largest pharmaceutical company and a direct peer across generic formulations, specialty, and global markets including the US. Both companies compete head-to-head in Indian branded generics, US ANDA filings, and emerging biosimilar opportunities.
• Cipla: Major Indian generic and specialty pharma player with overlapping therapy areas (respiratory, cardiology, anti-infectives) and a comparable US generics franchise. Alkem's former CEO Dr. Vikas Gupta joined from Cipla, underscoring operational similarity.
• Dr. Reddy's Laboratories: Direct peer in India branded generics, US generics, and biosimilars. Comparable in scale, ANDA pipeline depth, and therapy area breadth including oncology, gastroenterology, and pain management.
• Lupin: Indian pharma peer with strong chronic disease franchises (cardiology, diabetology, respiratory) and a significant US generics business. Overlaps with Alkem in anti-infectives, CNS, and women's health, with comparable manufacturing footprint and ANDA strategy.
• Aurobindo Pharma: Large Indian generic manufacturer with a similar mix of India domestic, US generics, and emerging market exposure. Competes directly in oral solids, injectables, and biosimilars with comparable API integration.
• Zydus Lifesciences: Indian pharma peer active across formulations, APIs, biosimilars (Exemptia, similar to MABVINRA), and consumer wellness. Overlaps with Alkem in biosimilars, US generics, and specialty therapy areas such as oncology and rheumatology.
• Torrent Pharmaceuticals: Indian pharma peer focused on chronic therapy areas (cardiology, diabetology, CNS) and US generics, with comparable ANDA strategy and similar India-international revenue mix.
• Glenmark Pharmaceuticals: Indian-headquartered pharma company with India branded generics, US generics, and respiratory focus. Overlaps with Alkem in chronic disease therapies and the Pulmocare-style respiratory franchise Alkem is building.
• Biocon: India-based biopharmaceutical peer with a strong biosimilars portfolio (Trastuzumab, Bevacizumab, Adalimumab, Rituximab) and global commercialization partnerships, directly comparable to Enzene's biosimilar ambitions.

Regional players

• Mankind Pharma: India-focused pharma major with strong domestic branded generics presence across anti-infectives, cardiology, and consumer health. Direct competitor in the Indian domestic market where Alkem derives the majority of its revenue.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Alkem_Lab
• YouTubeyoutube.com/@ALKEMOFFICIAL
• Facebookfacebook.com/alkemlabsltd
• LinkedInlinkedin.com/company/alkem-laboratories-ltd
• Instagraminstagram.com/alkemlabs?igsh=ZTN2aXF5b2Iwbjlx

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries16 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alkem Laboratories